These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1915 related articles for article (PubMed ID: 34764464)

  • 1. Immunotherapies for hepatocellular carcinoma.
    Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
    Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
    Weinmann A; Galle PR
    Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
    Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
    JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
    Donne R; Lujambio A
    Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular therapies for HCC: Looking outside the box.
    Faivre S; Rimassa L; Finn RS
    J Hepatol; 2020 Feb; 72(2):342-352. PubMed ID: 31954496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
    Lim H; Ramjeesingh R; Liu D; Tam VC; Knox JJ; Card PB; Meyers BM
    J Natl Cancer Inst; 2021 Feb; 113(2):123-136. PubMed ID: 32898239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: systemic treatment of hepatocellular carcinoma.
    Pinter M; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2018 Sep; 48(6):598-609. PubMed ID: 30039640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
    Rimassa L; Wörns MA
    Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma.
    Ferrarese A; Sciarrone SS; Pellone M; Shalaby S; Battistella S; Zanetto A; Germani G; Russo FP; Senzolo M; Burra P; Gambato M
    Minerva Gastroenterol (Torino); 2021 Mar; 67(1):4-10. PubMed ID: 33222429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic therapies for hepatocellular carcinoma: the present and the future.
    Celsa C; Giuffrida P; Stornello C; Grova M; Spatola F; Rizzo GEM; Busacca A; Cannella R; Battaglia S; Cammà C; Cabibbo G
    Recenti Prog Med; 2021 Feb; 112(2):110-116. PubMed ID: 33624623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.